Open AccessThis article is
- freely available
Ocular Drug Delivery for Glaucoma Management
Department of Bioengineering, University of Utah, Salt Lake City, UT, USA
Department of Pharmacy, University of Utah, Salt Lake City, UT, USA
Moran Eye Center, University of Utah, Salt Lake City, UT, USA
* Author to whom correspondence should be addressed.
Received: 22 December 2011; in revised form: 6 February 2012 / Accepted: 1 March 2012 / Published: 8 March 2012
Abstract: Current glaucoma management modalities are hindered by low patient compliance and adherence. This can be due to highly complex treatment strategies or poor patient understanding. Treatments focus on the management or reduction of intraocular pressure. This is most commonly done through the use of daily topical eye drops. Unfortunately, despite effective therapies, glaucoma continues to progress, possibly due to patients not adhering to their treatments. In order to mitigate these patient compliance issues, many sustained release treatments are being researched and are entering the clinic. Conjunctival, subconjunctival, and intravitreal inserts, punctal plugs, and drug depots are currently in clinical development. Each delivery system has hurdles, yet shows promise and could potentially mitigate the current problems associated with poor patient compliance.
Keywords: glaucoma; IOP; drug delivery; sustained release; polymer; inserts; punctal plug
Citations to this Article
Cite This Article
MDPI and ACS Style
Gooch, N.; Molokhia, S.A.; Condie, R.; Burr, R.M.; Archer, B.; Ambati, B.K.; Wirostko, B. Ocular Drug Delivery for Glaucoma Management. Pharmaceutics 2012, 4, 197-211.
Gooch N, Molokhia SA, Condie R, Burr RM, Archer B, Ambati BK, Wirostko B. Ocular Drug Delivery for Glaucoma Management. Pharmaceutics. 2012; 4(1):197-211.
Gooch, Nathan; Molokhia, Sarah A.; Condie, Russell; Burr, Randon Michael; Archer, Bonnie; Ambati, Balamurali K.; Wirostko, Barbara. 2012. "Ocular Drug Delivery for Glaucoma Management." Pharmaceutics 4, no. 1: 197-211.